Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed, Bristol-Myers Squibb, CG Oncology, Merck, Eli Lilly and Company, UroGen, Ferring

The dynamics of the bladder cancer market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies.

LAS VEGAS, Aug. 7, 2023 /PRNewswire/ -- DelveInsight's Bladder Cancer Market Insights report includes a comprehensive understanding of current treatment practices, bladder cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Bladder Cancer Market Report

• As per DelveInsight analysis, the bladder cancer market is expected to grow positively at a significant CAGR during the study period (2019–2032).
• Bladder cancer is ranked 10th among all cancers in the world with 549,000 cases and 200,000 deaths per year.
• Leading bladder cancer companies such as CicloMed LLC, EMD Serono, Taiho Oncology, Inc., Bristol-Myers Squibb, SURGE Therapeutics, CG Oncology, Inc., Aura Biosciences, Merck Sharp & Dohme LLC, Eli Lilly and Company, UroGen Pharma Ltd., Ferring Pharmaceuticals, FKD Therapies Oy, ImmunityBio, Inc., Janssen Research & Development, LLC, Protara Therapeutics, Pfizer, Hoffmann-La Roche, enGene, Inc., AstraZeneca, Seagen Inc., Astellas Pharma Inc, Incyte Corporation, ALX Oncology Inc., Fidia Farmaceutici s.p.a., Compass Therapeutics, Fusion Pharmaceuticals Inc., HiberCell, Inc., Ikena Oncology, and others are developing novel bladder cancer drugs that can be available in the bladder cancer market in the coming years.
• Some key therapies for bladder cancer treatment include CPX-POM, Avelumab, TAS 102, Nivolumab, STM-416, CG0070, AU-011, Pembrolizumab, Abemaciclib, UGN-102, ADSTILADRIN, N-803, TAR-200, TARA-002, PF-06801591, Atezolizumab, EG-70, AZD4547, Enfortumab vedotin, Pemigatinib, Evorpacept, ONCOFID P-B, CTX-009, [225Ac]-FPI-1966, HC-7366, IK-175, and others.

Discover which therapies are expected to grab the major bladder cancer market share @ Bladder Cancer Market Report

Bladder Cancer Overview

Bladder cancer is a prevalent form of cancer that develops in the tissues of the bladder, the organ responsible for storing urine. It is more commonly found in older individuals, particularly those over the age of 55, and is more prevalent in men than women. The exact causes of bladder cancer can be multifactorial, but certain risk factors increase the likelihood of developing this condition.

Bladder cancer may present with various symptoms, some of which can be subtle in the early stages. Common signs include blood in the urine, which is often painless, frequent urination, a burning sensation during urination, and an urgent need to urinate even when the bladder is not full. In more advanced cases, individuals may experience pelvic pain, back pain, unintended weight loss, and swelling in the legs. Diagnosing bladder cancer typically involves a series of tests and examinations. Initially, a physical examination is performed, followed by a review of the patient's medical history and risk factors.

Bladder Cancer Epidemiology Segmentation

The bladder cancer epidemiology section provides insights into the historical and current bladder cancerpatient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. 

The disease epidemiology covered in the report provides historical as well as forecasted bladder cancer epidemiology scenarios in the 7MM covering the United States, EU4 countries (Germany, Spain, Italy, France), the United Kingdom, and Japan from 2019 to 2032.

Bladder Cancer Treatment Market 

Bladder cancer treatment involves a comprehensive approach tailored to the specific stage and severity of the disease. The primary bladder cancer treatment options include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy. Surgical procedures aim to remove the cancerous tissue and may range from minimally invasive techniques to complete bladder removal in more advanced cases. Radiation therapy uses high-energy rays to target and destroy cancer cells, often combined with surgery or as a palliative option to relieve symptoms. 

Chemotherapy utilizes powerful drugs to kill rapidly dividing cancer cells and may be administered before or after surgery to prevent recurrence. Immunotherapy, on the other hand, enhances the body's immune system to recognize and attack cancer cells effectively. Targeted therapy focuses on specific molecular changes in cancer cells to impede their growth. The choice of treatment depends on factors such as the stage of cancer, the patient's overall health, and their preferences. Multidisciplinary care and ongoing monitoring are crucial to optimize outcomes and enhance the quality of life for individuals affected by bladder cancer.

In early-stage bladder cancer, non-invasive tumors that are confined to the inner lining of the bladder may be treated with transurethral resection (TURBT), a procedure in which a cystoscope is used to remove the tumor. After TURBT, intravesical therapy can be administered, which involves delivering chemotherapy or immunotherapy drugs directly into the bladder through a catheter to target any remaining cancer cells and prevent recurrence.

For more advanced or invasive bladder cancers, surgery may involve partial or radical cystectomy. A partial cystectomy removes a portion of the bladder, preserving bladder function, while radical cystectomy involves removing the entire bladder along with surrounding lymph nodes. In cases where the bladder is removed, reconstructive surgery, such as creating a new bladder or using an external bag, is performed to allow the patient to continue normal urine elimination.

To know more about bladder cancer treatment, visit @ Bladder Cancer Treatment Drugs 

Key Bladder Cancer Therapies and Companies

• CPX-POM: CicloMed LLC
• Avelumab: EMD Serono
• TAS 102: Taiho Oncology, Inc.
• Nivolumab: Bristol-Myers Squibb
• STM-416: SURGE Therapeutics
• CG0070: CG Oncology, Inc.
• AU-011: Aura Biosciences
• Pembrolizumab: Merck Sharp & Dohme LLC
• Abemaciclib: Eli Lilly and Company
• UGN-102: UroGen Pharma Ltd.
• ADSTILADRIN: Ferring Pharmaceuticals/FKD Therapies Oy
• N-803: ImmunityBio, Inc.
• TAR-200: Janssen Research & Development, LLC
• TARA-002: Protara Therapeutics
• PF-06801591: Pfizer
• Atezolizumab: Hoffmann-La Roche
• EG-70: enGene, Inc.
• AZD4547: AstraZeneca
• Enfortumab vedotin: Seagen Inc./Astellas Pharma Inc
• Pemigatinib: Incyte Corporation
• Evorpacept: ALX Oncology Inc.
• ONCOFID P-B: Fidia Farmaceutici s.p.a.
• CTX-009: Compass Therapeutics
• [225Ac]-FPI-1966: Fusion Pharmaceuticals Inc.
• HC-7366: HiberCell, Inc.
• IK-175: Ikena Oncology

Learn more about the FDA-approved drugs for bladder cancer @ Drugs for Bladder Cancer Treatment 

Bladder Cancer Market Dynamics

The bladder cancer market dynamics have been undergoing significant changes, primarily driven by advancements in medical research and technology. The development and approval of novel targeted therapies and immunotherapies have brought about a paradigm shift in the treatment landscape, providing more effective and personalized options for patients. Moreover, increased awareness about early detection and screening programs has led to the diagnosis of bladder cancer at earlier stages, enabling more favorable treatment outcomes and improving patient survival rates. This growing emphasis on early intervention has driven pharmaceutical companies and biotech firms to invest in research and development, leading to a competitive and innovative market environment.

Additionally, the healthcare industry's shift towards value-based care and the incorporation of precision medicine has further fueled the demand for tailored treatment approaches. Collaborations between pharmaceutical companies, research institutions, and advocacy groups have facilitated the development of targeted therapies, fostering a more patient-centric approach to bladder cancer management.

However, despite these advancements, challenges persist in the bladder cancer market. High treatment costs, reimbursement issues, and the availability of generic alternatives continue to impact the accessibility and affordability of these advanced therapies for some patients. Additionally, regulatory requirements and the lengthy approval process for new treatments pose hurdles to bladder cancer market entry, potentially limiting the diversity of available options.

Scope of the Bladder Cancer Market Report

• Therapeutic Assessment: Bladder Cancer current marketed and emerging therapies
• Bladder Cancer Market Dynamics: Conjoint Analysis of Emerging Bladder Cancer Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Bladder Cancer Market Access and Reimbursement

Discover more about bladder cancer drugs in development @ Bladder Cancer Clinical Trials

Table of Contents

Related Reports

Bladder Cancer Pipeline

Bladder Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key bladder cancer companies, including CG Oncology, FKD Therapies, Bristol-Myers Squibb, LintonPharm Co., Ltd., ImmunityBio, Inc., Hamlet Pharma AB, Asieris Pharmaceuticals, Pfizer, Taizhou Hanzhong biomedical co. LTD, Protara Therapeutics, CicloMed LLC, enGene, Inc., Emtora Biosciences, Theralase Inc.,  Vaxiion Therapeutics, Janssen Research & Development, LLC, Astellas Pharma, RemeGen Co., Ltd., UroGen Pharma Ltd., Flame Biosciences, Aura Biosciences, BeiGene, Incyte Corporation, QED Therapeutics, G1 Therapeutics, AN0025, Kyowa Kirin, Inc., Infinity Pharmaceuticals, Shanghai Hengrui Pharmaceutical Co., Ltd., HiberCell, Inc., Ikena Oncology, Genentech, Fusion Pharmaceuticals, GI Innovation,SOTIO Biotech AG, Celon Pharma SA, 4D Pharma PLC, Keythera Pharmaceuticals, Quadriga Biosciences, Inc., NeoTX Therapeutics Ltd., Mirati Therapeutics, NGM Biopharmaceuticals, TransThera Biosciences, Ocellaris Pharma, Palleon Pharmaceuticals, Medicenna Therapeutics, Klus Pharma, Novartis, Toray Industries, Carisma Therapeutics, Avacta Life Sciences Ltd, Seagen Inc., Elevation Oncology, Corvus Pharmaceuticals, ADC Therapeutics S.A., IO Biotech, Byondis B.V., Takara Bio, Seven and Eight Biopharmaceuticals, Dragonfly Therapeutics, InnoCare Pharma, among others.

Bladder Cancer Epidemiology Forecast

Bladder Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted bladder cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Non-Muscle Invasive Bladder Cancer Pipeline

Non-Muscle Invasive Bladder Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-muscle invasive bladder cancer companies, including UroGen Pharma, CG Oncolgy, Sasanlimab, Sesen Bio, Theralase Technologies, Asieris Pharmaceuticals, Hamlet Pharma, AstraZeneca, Viralytics, ImmunityBio, Prokarium, among others.

Muscle-Invasive Bladder Cancer Market

Muscle-Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key muscle-invasive bladder cancer companies including SOTIO a.s., Celon Pharma SA, Shanghai PerHum Therapeutics Co., Ltd., 4D Pharma PLC, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
[email protected]   
+1(919)321-6187
www.delveinsight.com  

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg 

SOURCE DelveInsight Business Research, LLP